Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HTR5A | P47898 | 1/20 | 0.43 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6526481 | 1.00 | LMNA (0.45) | LMNAMAPTBAZ2BHTR2AHTR2C | |
| SCHEMBL11838605 | 0.83 | LMNA (0.47) | LMNAMAPTBAZ2BHTR2AHTR2C | |
| SCHEMBL4969326 | 0.81 | MAPT (0.43) | LMNAMAPTBAZ2BHTR2AHTR2C | |
| SCHEMBL11204300 | 0.80 | HTR2A (0.47) | LMNAMAPTBAZ2BHTR2AHTR2C | |
| SCHEMBL5881040 | 0.79 | BAZ2B (0.53) | LMNABAZ2BSIRT1 | |
| SCHEMBL5881078 | 0.79 | MAPKAPK2 (0.52) | LMNAMAPTKDM4EALDH1A1 | |
| SCHEMBL31684725 | 0.77 | HTR2A (0.46) | HTR2AHTR2CNR2E1KDM4EHTR5A | |
| SCHEMBL6529663 | 0.77 | HTR2A (0.49) | LMNAMAPTBAZ2BHTR2AHTR2C | |
| SCHEMBL4651124 | 0.76 | HTR2A (0.45) | LMNAMAPTBAZ2BHTR2AHTR2C | |
| SCHEMBL4652083 | 0.76 | HTR2A (0.45) | LMNAMAPTBAZ2BHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100500654-C | Tetrahydrocarbazole derivatives as ligands for G-protein coupled receptors (GPCRs) | ZENTARIS AG (DE) | 2009-06-17 | — | — | CN | claimed |
| US-7122570-B2 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2006-10-17 | — | — | US | claimed |
| WO-2005047247-A1 | NOVEL1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2005-05-26 | — | — | WO | claimed |
| CN-1599720-A | Tetrahydrocarbazole derivatives as ligands for G-protein coupled receptors (GPCRs) | ZENTARIS AG (DE) | 2005-03-23 | — | — | CN | claimed |
| US-20030232873-A1 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2003-12-18 | — | — | US | claimed |
| US-8541462-B2 | Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors | AETERNA ZENTARIS GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20120122763-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| US-8148546-B2 | Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors | AETERNA ZENTARIS GMBH (DE) | 2012-04-03 | — | — | US | disclosed |
| US-8088890-B2 | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2012-01-03 | — | — | US | disclosed |
| US-8088890-B2 | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2012-01-03 | — | — | US | disclosed |
| US-8067456-B2 | Tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCPs) | AETERNA ZENTARIS GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| WO-2011060018-A2 | COMPOSITIONS AND METHODS FOR USING PEPTIDES, MODIFIED PEPTIDES, PEPTIDOMIMETICS AND FIBRIN DERIVATIVES | IKARIA DEVELOPMENT SUBSIDIARY TWO LLC (US) | 2011-05-19 | — | — | WO | disclosed |
| US-7122570-B2 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2006-10-17 | — | — | US | disclosed |
| WO-2006005484-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES WITH IMPROVED BIOLOGICAL ACTION AND IMPROVED SOLUBILITY AS LIGANDS FOR G-PROTEIN COUPLED RECEPTORS (GPCRS) | ZENTARIS GMBH (DE) | 2006-01-19 | — | — | WO | disclosed |
| US-20060014818-A1 | Novel tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCRs) | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2006-01-19 | — | — | US | disclosed |
| WO-2005033099-A2 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS; PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2005-04-14 | — | — | WO | disclosed |
| CN-1599720-A | Tetrahydrocarbazole derivatives as ligands for G-protein coupled receptors (GPCRs) | ZENTARIS AG (DE) | 2005-03-23 | — | — | CN | disclosed |
| EP-1453803-A2 | TETRAHYDROCARBOZOLE DERIVATIVES AS LIGANDS FOR G-PROTEIN COUPLED RECEPTORS (GPCR) | Zentaris GmbH (DE) | 2004-09-08 | — | — | EP | disclosed |
| US-20030232873-A1 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003051837-A2 | TETRAHYDROCARBOZOLE DERIVATIVES AS LIGANDS FOR G-PROTEIN COUPLED RECEPTORS (GPCR) | ZENTARIS GMBH (DE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122763-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR88, GPR34, GPR27 | LMNA 3715/4885MAPT 3996/4885BAZ2B 1232/4885 |
| US-20030232873-A1 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | GPR4, GPR88, GPR35 | LMNA 4253/4885MAPT 2593/4885BAZ2B 1032/4885 |
| US-20060014818-A1 | Novel tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCRs) | GPR88, GPR34, GPR35 | LMNA 3646/4885MAPT 3394/4885BAZ2B 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.